Effect of proteinase inhibitor Camostat Mesilate on nephrotic syndrome with diabetic nephropathy

T. Onbe, H. Makino, I. Kumagai, T. Haramoto, K. Murakami, Z. Ota

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

The effect of serine protease inhibitor Camostat Mesilate on nephrotic syndrome with diabetic nephropathy was evaluated. Eight patients with nephrotic syndrome associated with diabetic nephropathy were orally administered 600 mg of Camostat Mesilate per day. Three patients showed a reduction of urinary protein excretion promptly at 4 weeks. Serum protein and degree of edema improved significantly at 4 weeks. Camostat Mesilate had no effect on renal function assessed by creatinine clearance. During the observation period there were no significant changes in blood pressure, level of blood sugar, or HbA1c. Camostat Mesilate would be beneficial for the treatment of diabetic nephropathy.

Original languageEnglish
Pages (from-to)167-168
Number of pages2
JournalJournal of Diabetic Complications
Volume5
Issue number2-3
DOIs
Publication statusPublished - Jan 1 1991

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Fingerprint Dive into the research topics of 'Effect of proteinase inhibitor Camostat Mesilate on nephrotic syndrome with diabetic nephropathy'. Together they form a unique fingerprint.

  • Cite this